2018
DOI: 10.1111/bph.14429
|View full text |Cite
|
Sign up to set email alerts
|

Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration‐approved drugs

Abstract: Our results identify imipramine as a new pharmacological tool to study macropinocytosis in cellular and biological systems. This study also suggests that imipramine could be a good candidate for repurposing as a therapeutic agent in pathological processes involving macropinocytosis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
91
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 98 publications
(93 citation statements)
references
References 60 publications
2
91
0
Order By: Relevance
“…Identification of novel molecular machinery regulating macropinocytosis will aid future studies and may pave the way to specifically modulate macropinocytosis in vitro and in vivo. With the application of small-molecule inhibitors [55], siRNA libraries [120] and CRISPR libraries, there are exciting opportunities for high-throughput screens to be performed to identify novel macropinocytosis regulators. Ultimately, a greater understanding of the different pathways of macropinocytosis in different cell types will provide the potential to modulate individual functions which are regulated by these endocytic pathways.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Identification of novel molecular machinery regulating macropinocytosis will aid future studies and may pave the way to specifically modulate macropinocytosis in vitro and in vivo. With the application of small-molecule inhibitors [55], siRNA libraries [120] and CRISPR libraries, there are exciting opportunities for high-throughput screens to be performed to identify novel macropinocytosis regulators. Ultimately, a greater understanding of the different pathways of macropinocytosis in different cell types will provide the potential to modulate individual functions which are regulated by these endocytic pathways.…”
Section: Resultsmentioning
confidence: 99%
“…Our understanding of the different pathways of macropinocytosis, such as constitutive versus growth factor-induced macropinocytosis, and dorsal versus peripheral ruffling pathways of macropinocytosis, largely result from the studies using macrophages. Macrophages from a variety sources have been used to study macropinocytosis, in particular primary mouse bone marrow-derived macrophages (BMDMs) [9,17], primary mouse peritoneal macrophages [17], the macrophage cell line RAW 264.7 [54,55] and human monocyte-derived macrophages (hMDMs) [45,56].…”
Section: Macrophagesmentioning
confidence: 99%
“…Among nonclathrinmediated endocytic processes, macropi nocytosis mediates the uptake of nutrients and extracellular flu id into cells (35). However, neither EIPA, an amiloride derivative inhibiting Na + /H + exchange needed for macropinosome matura tion (36), nor imipramine, a newly identified selective inhibitor of macropinocytosis (37), interfered with antibody transfer (Figure 8, E and F, and Supplemental Figure 6, E-H). Since many endocytosis routes are dynamin dependent, we tested the effect of dynamin inhibitors on the transfer of anti bodies.…”
Section: Resultsmentioning
confidence: 99%
“…As shown in Figure A,B, a substantial part of the biotinylated claudin‐1 was resistant to stripping, which is a biochemical demonstration of the endocytosis of claudin‐1 in SAS cells. In addition, endocytosis of claudin‐1 in SAS cells was investigated in the presence of an inhibitor of clathrin‐dependent endocytosis, CPZ, and an inhibitor of macropinocytosis, IMP . Addition of IMP decreased the extent of stripping‐resistant claudin‐1, suggesting that IMP inhibited claudin‐1 endocytosis.…”
Section: Resultsmentioning
confidence: 99%